Nicox Postpones NASDAQ Listing Due to Market Volatility
October 30, 2018
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time. The purpose of a Nasdaq listing is to allow the extensive U.S. healthcare and biotech investor community better access to Nicox’s stock, and to gain equity research coverage by U.S. specialist analysts.